articleNew England Journal of MedicineDec 3, 2008BRONZE OA

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

Michigan Medicine · SUNY Downstate Health Sciences University · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic.

Methods

In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.

Citation impact

2,071
total citations
FWCI
128.70
Percentile
100%
References
21
Citations per year

Authors

10

Topics & keywords

Keywords
  • Medicine
  • Benazepril
  • Amlodipine
  • Hydrochlorothiazide
  • Internal medicine
  • Cardiology
  • Myocardial infarction
  • Hazard ratio
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding